Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
lamivudine, Quantity: 150 mg; zidovudine, Quantity: 300 mg
ViiV Healthcare Pty Ltd
Tablet, film coated
Excipient Ingredients: magnesium stearate; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 4000
Oral
60 tablets
(S4) Prescription Only Medicine
Combivir is indicated for use alone or in combination with other antiretroviral therapies in the treatment of HIV infection.
Visual Identification: White to off-white film-coated, capsule-shaped, scored tablet engraved with "GXFC3" on both tablet face. Each tablet contains lamivudine 150 mg and zidovudine 300 mg; Container Type: Bottle; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
1998-01-23
1 AUSTRALIAN PRODUCT INFORMATION COMBIVIR (LAMIVUDINE AND ZIDOVUDINE) FILM-COATED TABLETS 1 NAME OF THE MEDICINE Lamivudine and zidovudine 2 QUALITATIVE AND QUANTITATIVE COMPOSITION COMBIVIR Tablets are a fixed combination product containing lamivudine 150 mg and zidovudine 300 mg in each tablet. Product information for 3TC (tablets and oral solution) and RETROVIR (capsules and syrup) contain additional information specific for lamivudine and zidovudine, respectively. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM COMBIVIR tablets are available as both scored and unscored tablets. COMBIVIR unscored tablets are white to off-white capsule-shaped film-coated tablets, engraved with “GXFC3” on one tablet face. COMBIVIR scored tablets are white to off-white capsule-shaped film-coated tablets, engraved with “GXFC3” on both tablet faces. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS COMBIVIR is indicated for use alone or in combination with other antiretroviral therapies in the treatment of HIV infection. 4.2 DOSE AND METHOD OF ADMINISTRATION COMBIVIR may be administered with or without food. Food reduces the C max and extends the T max of lamivudine but the amount of drug absorbed is not reduced. The clinical significance of this is not known (see Section 5.2 PHARMACOKINETIC PROPERTIES). For situations where discontinuation of therapy with one of the active constituents of COMBIVIR, or dose reduction is necessary, separate preparations of lamivudine (3TC tablets and oral solution) and zidovudine (RETROVIR Capsules and Syrup) are available. To ensure administration of the entire dose, the tablet(s) should ideally be swallowed without crushing. For patients who are unable to swallow tablets, the tablet(s) may be crushed and 100% of the crushed tablet could be added to a small amount of semi-solid food or liquid, all of which should be consumed immediately (see Section 5.2 PHARMACOKINETIC PROPERTIES). 2 The dosing regimens for paediatric patients weighing 14-30 kg is Lugege kogu dokumenti